Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 213 of 6351
-
New cocktail aims to stall breast cancer spread in Hard-to-Treat cases
Disease control Recruiting nowThis study is an open-label, multicenter, randomized controlled study. It is planned to include 258 patients with HR +/HER2- advanced breast cancer with visceral metastases. Eligible subjects will be randomized 1:1 to receive dalpiciclib in combination with endocrine therapy and …
Phase 3 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New mRNA shingles vaccine shows promise in Mid-Stage trial
Vaccine OngoingThe primary objective of this study is to evaluate the immunogenicity and safety of 2 injections (approximately 2 months apart) of ABO1108 in adults aged 40 years or above.
Phase 2 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 12:31 UTC
-
Could a quick blood thinner before stroke surgery boost recovery?
Disease control Recruiting nowIt remains uncertain whether intravenous tirofiban administered before endovascular thrombectomy could improve disability severity for patients with LVO due to intracranial atherosclerosis.The current study aimed to assess the efficacy and safety of administering intravenous tiro…
Phase 3 • Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New combo before liver surgery aims to stop cancer return
Disease control Recruiting nowThis is an open-label, single-arm, multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of TACE combined with Atezolizumab and Bevacizumab as neoadjuvant treatment in Hepatocellular Carcinoma.
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New shot could help patients with severe blistering skin disease ditch steroids
Disease control Not yet recruitingThis study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Stapokibart in subjects with Moderate to Severe Bullous Pemphigoid.
Phase 3 • Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Lung cancer trial aims to match treatments to tumor type
Disease control Recruiting nowThis phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer cells that may give doctors more informat…
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Engineered immune cells take on brain cancer in pioneering trial
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
Phase 2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can donor immune cells fight leukemia relapse after transplant?
Disease control Recruiting nowThis is a single-centre, single-arm, open-label, early clinical study to evaluate the safety, tolerability and preliminary efficacy of donor NK cells injection combined with low-dose interleukin-2 in the treatment of acute myeloid leukemia (AML) relapse after allogeneic hematopoi…
Phase 1 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug aims to outsmart recurrent lymphoma
Disease control Not yet recruitingEvaluation of the efficacy and safety of TQB2825 injection compared to immunotherapy in the treatment of recurrent/refractory follicular lymphoma.
Phase 3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
First gene therapy for rare brain disorder begins testing in kids
Disease control Recruiting nowThe goal of this first in human, phase I/II clinical trial is to evaulate the safety, tolerability, and preliminary efficacy of AAV9 mediated gene replacement therapy (Urbagen) in paediatric patients with CTNNB1 neurodevelopmental disorder. The main questions it aims to answer ar…
Phase 1/2 • Sponsor: CTNNB1 Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Double-Barreled CAR-T attack on Hard-to-Treat myeloma shows promise
Disease control Recruiting nowThis study aims to investigate the efficacy and safety of CD19/BCMA CAR-T cells in treating relapsed/refractory multiple myeloma.
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug duo aims to shrink aggressive breast cancer before surgery
Disease control Not yet recruitingThis is a prospective, single center, phase II study to enroll participants with stage II or III TNBC who have not previously undergone systemic therapy. The primary endpoint is pCR in the ITT population. The study aims to enroll 52 participants. Eligible participants will receiv…
Phase 2 • Sponsor: Yantai Yuhuangding Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New combo therapy aims to extend life in hard-to-treat head and neck cancer
Disease control Recruiting nowProspective, open-label, randomized controlled phase III trail that aims to investigate whether Re-Radiochemotherapy (Re-RCT) and sequential immunotherapy with pembrolizumab improves overall survival compared to the standard treatment with pembrolizumab alone (± chemotherapy) in …
Phase 3 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
AI predicts liver cancer return, guides personalized drug cocktail
Disease control Recruiting nowThis study is for patients with early-stage liver cancer who are planning to have surgery. The goal of this research is to see if a personalized treatment plan, guided by a computer model (an artificial intelligence tool), can help prevent the cancer from coming back after surger…
Phase 1/2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
One-Shot gene therapy aims to end monthly eye injections for wet AMD
Disease control Not yet recruitingVEGF inhibitors (anti-VEGF),such as aflibercept has been shown to be safe and effective for treating nAMD and have demonstrated improvement in vision. However, anti-VEGF therapy is administered frequently via intravitreal injection and can be a significant burden to the patients.…
Phase 1/2 • Sponsor: Guangzhou Jiayin Biotech Ltd • Aim: Disease control
Last updated Jun 26, 2026 17:51 UTC
-
Glaucoma patients may soon ditch eye drops after cataract surgery
Disease control Recruiting nowThis trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
Phase 3 • Sponsor: SpyGlass Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Can a pill clear the toxic proteins behind Alzheimer's?
Disease control OngoingThe study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with MCI or Alzheimer's Disease (AD). In the study participants receive increasing dose of active treatment (250mg vs 500mg vs 750mg) or matched placebo in the form of tab…
Phase 2 • Sponsor: Arctic Therapeutics • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New targeted pill takes on Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis is a multicenter, open-label, phase Ⅱa study to explore the safety, tolerability, and preliminary efficacy of RNK08954 in metastatic pancreatic ductal adenocarcinoma harboring a KRAS G12D mutation.
Phase 2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug could boost survival after cardiac arrest by calming Body's overreaction
Disease control OngoingThe investigators assessed the effect of TNF-α antagonism within 6 hours of return of spontaneous circulation on 30-day mortality in patients who remained comatose after cardiopulmonary resuscitation (CPR) following cardiac arrest . In addition, the investigators explored the rol…
Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immune reset: CAR-T therapy takes on autoimmune diseases
Disease control Recruiting nowIn this study, CD19 CAR-T cells were administered to patients with relapsed/refractory autoimmune diseases. This study intends to use retroviral vector-based tandem CAR-T cells targeting CD19 to treat autoimmune disease. The CAR-T cells were provided by Shenzhen Cell Valley. A st…
Sponsor: ShenZhen Cell Valley • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC